The complexity of sunitinib dosing in renal cell cancer patients

por Desar, Ingrid M.E., Mulder, Sasja F., Mulders, Peter F.A., van Herpen, Carla M.L.
Publicado 2012

The relationship between sunitinib exposure and both efficacy and toxicity in real‐world patients with renal cell carcinoma and gastrointestinal stromal tumour

por Westerdijk, Kim, Krens, Stefanie D., van der Graaf, Winette T.A., Mulder, Sasja F., van Herpen, Carla M.L., Smilde, Tineke, van Erp, Nielka P., Desar, Ingrid M.E.
Publicado 2020

(68)Ga-PSMA-HBED-CC PET/CT imaging for adenoid cystic carcinoma and salivary duct carcinoma: a phase 2 imaging study

por van Boxtel, Wim, Lütje, Susanne, van Engen-van Grunsven, Ilse C.H., Verhaegh, Gerald W., Schalken, Jack A., Jonker, Marianne A., Nagarajah, James, Gotthardt, Martin, van Herpen, Carla M.L.
Publicado 2020

Impairment of cognitive functioning during Sunitinib or Sorafenib treatment in cancer patients: a cross sectional study

por Mulder, Sasja F, Bertens, Dirk, Desar, Ingrid ME, Vissers, Kris CP, Mulders, Peter FA, Punt, Cornelis JA, van Spronsen, Dick-Johan, Langenhuijsen, Johan F, Kessels, Roy PC, van Herpen, Carla ML
Publicado 2014

Experimental treatment of NRAS-mutated neurocutaneous melanocytosis with MEK162, a MEK-inhibitor

por Küsters-Vandevelde, Heidi VN, Willemsen, Annelieke ECAB, Groenen, Patricia JTA, Küsters, Benno, Lammens, Martin, Wesseling, Pieter, Djafarihamedani, Melika, Rijntjes, Jos, Delye, Hans, Willemsen, Michel A, van Herpen, Carla ML, Blokx, Willeke AM
Publicado 2014

Kidney absorbed radiation doses for [(177)Lu]Lu-PSMA-617 and [(177)Lu]Lu-PSMA-I&T determined by 3D clinical dosimetry

por Uijen, Maike J.M., Privé, Bastiaan M., van Herpen, Carla M.L., Westdorp, Harm, van Gemert, Willemijn A., de Bakker, Maarten, Gotthardt, Martin, Konijnenberg, Mark W., Peters, Steffie M.B., Nagarajah, James
Publicado 2023

Merkel Cell Carcinoma: New Trends

por Zwijnenburg, Ellen M., Lubeek, Satish F.K., Werner, Johanna E.M., Amir, Avital L., Weijs, Willem L.J., Takes, Robert P., Pegge, Sjoert A.H., van Herpen, Carla M.L., Adema, Gosse J., Kaanders, Johannes H. A. M.
Publicado 2021

Cisplatin inhibits frequency and suppressive activity of monocytic myeloid-derived suppressor cells in cancer patients

por Van Wigcheren, Glenn F., De Haas, Nienke, Mulder, Tom A., Horrevorts, Sophie K., Bloemendal, Martine, Hins-Debree, Simone, Mao, Yumeng, Kiessling, Rolf, van Herpen, Carla M.L., Flórez-Grau, Georgina, Hato, Stanleyson V., De Vries, I. Jolanda M.
Publicado 2021

Humoral and cellular immune responses after influenza vaccination in patients with postcancer fatigue

por Prinsen, Hetty, van Laarhoven, Hanneke WM, Pots, Jeanette M, Duiveman-de Boer, Tjitske, Mulder, Sasja F, van Herpen, Carla ML, Jacobs, Joannes FM, Leer, Jan Willem H, Bleijenberg, Gijs, Stelma, Foekje F, Torensma, Ruurd, de Vries, I Jolanda M
Publicado 2015

Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma

por van Herpen, Carla M.L., Agarwala, Sanjiv S., Hauschild, Axel, Berking, Carola, Beck, J. Thaddeus, Schadendorf, Dirk, Jansen, Rob, Queirolo, Paola, Ascierto, Paolo A., Blank, Christian U., Heinrich, Michael C., Pal, Rupam R., Derti, Adnan, Antona, Victor, Nauwelaerts, Heidi, Zubel, Angela, Dummer, Reinhard
Publicado 2019

Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma

por Schuler, Martin, Zimmer, Lisa, Kim, Kevin B., Sosman, Jeffrey A., Ascierto, Paolo A., Postow, Michael A., De Vos, Filip Y.F.L., van Herpen, Carla M.L., Carlino, Matteo S., Johnson, Douglas B., Berking, Carola, Reddy, Micaela B., Harney, Allison S., Berlin, Jordan D., Amaria, Rodabe N.
Publicado 2022

Myeloid-derived suppressor cells and tolerogenic dendritic cells are distinctively induced by PI3K and Wnt signaling pathways

por van Wigcheren, Glenn F., Cuenca-Escalona, Jorge, Stelloo, Suzan, Brake, Julia, Peeters, Eline, Horrevorts, Sophie.K., Frölich, Siebren, Ramos-Tomillero, Iván, Wesseling-Rozendaal, Yvonne, van Herpen, Carla M.L., van de Stolpe, Anja, Vermeulen, Michiel, de Vries, I. Jolanda M., Figdor, Carl G., Flórez-Grau, Georgina
Publicado 2023

Direct inhibition of STAT signaling by platinum drugs contributes to their anti-cancer activity

por Hato, Stanleyson V., Figdor, Carl G., Takahashi, Susumu, Pen, Anja E., Halilovic, Altuna, Bol, Kalijn F., Vasaturo, Angela, Inoue, Yukie, de Haas, Nienke, Verweij, Dagmar, Van Herpen, Carla M.L., Kaanders, Johannes H., van Krieken, Johan H.J.M., Van Laarhoven, Hanneke W.M., Hooijer, Gerrit K.J., Punt, Cornelis J.A., Asai, Akira, de Vries, I. Jolanda M., Lesterhuis, W.J.
Publicado 2017

[(89)Zr]Zr-DFO-girentuximab and [(18)F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma

por Verhoeff, Sarah R., Oosting, Sjoukje F., Elias, Sjoerd G., van Es, Suzanne C., Gerritse, Sophie L., Angus, Lindsay, Heskamp, Sandra, Desar, Ingrid M.E., Menke-van der Houven van Oordt, C. Willemien, van der Veldt, Astrid A.M., Arens, Anne I.J., Brouwers, Adrienne H., Eisses, Bertha, Mulders, Peter F.A., Hoekstra, Otto S., Zwezerijnen, Gerben J.C., van der Graaf, Winette T.A., Aarntzen, Erik H.J.G., Oyen, Wim J.G., van Herpen, Carla M.L.
Publicado 2023

Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment

por Hoes, Louisa R., van Berge Henegouwen, Jade M., van der Wijngaart, Hanneke, Zeverijn, Laurien J., van der Velden, Daphne L., van de Haar, Joris, Roepman, Paul, de Leng, Wendy J., Jansen, Anne M.L., van Werkhoven, Erik, van der Noort, Vincent, Huitema, Alwin D.R., Gort, Eelke H., de Groot, Jan Willem B., Kerver, Emile D., de Groot, Derk Jan, Erdkamp, Frans, Beerepoot, Laurens V., Hendriks, Mathijs P., Smit, Egbert F., van der Graaf, Winette T.A., van Herpen, Carla M.L., Labots, Mariette, Hoeben, Ann, Morreau, Hans, Lolkema, Martijn P., Cuppen, Edwin, Gelderblom, Hans, Verheul, Henk M.W., Voest, Emile E.
Publicado 2022